{"id":170073,"date":"2025-08-12T05:27:26","date_gmt":"2025-08-12T09:27:26","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170073"},"modified":"2025-08-12T05:27:41","modified_gmt":"2025-08-12T09:27:41","slug":"gland-pharma-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gland-pharma-q1-fy26-earnings-results\/","title":{"rendered":"Gland Pharma Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Gland Pharma Limited, established in Hyderabad, India in 1978, has evolved from being a contract manufacturer of small-volume liquid parenteral products to becoming one of the largest and fastest-growing injectable-focused companies in the world. With a presence in over 60 countries\u2014including the United States, Europe, Canada, Australia, and India\u2014the company operates primarily under a B2B model, boasting a strong track record in developing, manufacturing, and marketing complex injectables. It is promoted by Shanghai Fosun Pharma, a global pharmaceutical major. Presenting below are its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ee44c072-4ee8-4c49-8667-ada77a9b3440.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b91,506 crore, up 7.42% year-on-year (YoY) from \u20b91,402 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b91,251 crore, up 1.3% YoY from \u20b91,235 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9215 crore, up 49.31% from \u20b9144 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b913.08, up 49.83% from \u20b98.73 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Revenue Growth:<\/strong> The 7% increase in revenue was driven by steady demand across regulated and emerging markets, buoyed by product launches and deeper penetration in key geographies.<\/li>\n<li><strong>Controlled Cost Growth:<\/strong> Expenses grew by just 1.3%, significantly lower than revenue growth, reflecting strong operational efficiencies, supply chain optimization, and effective cost control measures.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ee44c072-4ee8-4c49-8667-ada77a9b3440.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Strong Profitability Expansion<\/strong><\/a><strong>:<\/strong> Net profit and EPS surged nearly 50%, supported by higher gross margins, favorable product mix, and improved manufacturing leverage.<\/li>\n<li><strong>Global Market Focus:<\/strong> Gland Pharma continues to strengthen its injectable portfolio and deepen its market presence in the US, Europe, and emerging economies, capitalizing on its expertise in complex molecules and technologies.<\/li>\n<li><strong>Innovation &amp; Integration:<\/strong> The company is investing in R&amp;D for niche sterile injectables and leveraging synergies with Fosun Pharma\u2019s global network for new product development and market access.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ee44c072-4ee8-4c49-8667-ada77a9b3440.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results highlight Gland Pharma\u2019s ability to deliver robust profit growth despite moderate revenue expansion. Strategic efficiency measures and a focus on high-value products have significantly boosted profitability.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170074\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png\" alt=\"GLAND Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Gland Pharma Ltd aims to sustain growth by expanding its injectable portfolio, accelerating new product filings in regulated markets, and enhancing manufacturing capacities. The company\u2019s strong pipeline, operational discipline, and global market reach are expected to drive continued margin expansion and shareholder value through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/gland\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma Limited, established in Hyderabad, India in 1978, has evolved from being a contract manufacturer of small-volume liquid parenteral products to becoming one of the largest and fastest-growing injectable-focused companies in the world. With a presence in over 60 countries\u2014including the United States, Europe, Canada, Australia, and India\u2014the company operates primarily under a B2B [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170074,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170207,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":170073,"position":0},"title":"Astrazeneca Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 15, 2025","format":false,"excerpt":"AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25. Total Expenses: \u20b9726 crore, up 20.40% YoY from \u20b9603 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ASTRAZEN Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178326,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":170073,"position":1},"title":"Gland Pharma Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of \u20b91,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to \u20b9261 crore. Total expenses increased 20.03% YoY to \u20b91,372 crore, reflecting strong revenue growth with controlled cost escalation. Revenue & Growth Revenues grew to \u20b91,695.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172355,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":170073,"position":2},"title":"Orchid Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 12, 2025","format":false,"excerpt":"Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b9193.52 crore, down 13.1% YoY but up 11.9% QoQ EBITDA: \u20b9-1.48 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Orchid Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":170073,"position":3},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":170073,"position":4},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172230,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":170073,"position":5},"title":"Mankind Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b93,697.16 crore, up 20.77% YoY and 3.55% QoQ. EBITDA: \u20b9924 crore, with an EBITDA margin of 25.0%, representing\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Mankind Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170073"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170073\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170074"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}